Welcome to CDC stacks | Preservation of β-Cell Function in Autoantibody-Positive Youth With Diabetes - 22876 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
Clear All Simple Search
Advanced Search
Preservation of β-Cell Function in Autoantibody-Positive Youth With Diabetes
Filetype[PDF-224.10 KB]

  • Corporate Authors:
    for the SEARCH Study Group*
  • Pubmed ID:
  • Pubmed Central ID:
  • Description:

    To determine the extent of β-cell function in youth with diabetes and GAD65 and/or IA2 autoantibodies.


    Fasting C-peptide levels from 2,789 GAD65- and/or IA2 autoantibody-positive youth aged 1–23 years from the SEARCH for Diabetes in Youth study were used. Preserved β-cell function was defined on the basis of cut points derived from the Diabetes Control and Complications Trial (DCCT) (fasting C-peptide ≥0.23 ng/ml) and from the U.S. adolescent population of the National Health and Nutrition Examination Survey (NHANES) 5th percentile for fasting C-peptide (≥1.0 ng/ml). We compared the clinical characteristics between those with and without preserved β-cell function.


    Within the first year of diagnosis, 82.9% of youth had a fasting C-peptide ≥0.23 ng/ml and 31.2% had values ≥1.0 ng/ml. Among those with ≥5 years of diabetes duration, 10.7% had preserved β-cell function based on the DCCT cutoff and 1.0% were above the 5th percentile of the NHANES population.


    Within the 1st year of diagnosis, four of five youth with autoantibody-positive diabetes have clinically significant amounts of residual β-cell function and about one-third have fasting C-peptide levels above the 5th percentile of a healthy adolescent population. Even 5 years after diagnosis, 1 of 10 has fasting C-peptide above a clinically significant threshold. These findings have implications for clinical classification of youth with diabetes as well as clinical trials aimed to preserve β-cell function after diabetes onset.

  • Document Type:
  • Collection(s):
  • Funding:
    M01 RR00069/RR/NCRR NIH HHS/United States
    M01 RR01070/RR/NCRR NIH HHS/United States
    M01 RR08084/RR/NCRR NIH HHS/United States
    M01RR00037/RR/NCRR NIH HHS/United States
    M01RR001271/RR/NCRR NIH HHS/United States
    U01 DP000244/DP/NCCDPHP CDC HHS/United States
    U01 DP000245/DP/NCCDPHP CDC HHS/United States
    U01 DP000246/DP/NCCDPHP CDC HHS/United States
    U01 DP000247/DP/NCCDPHP CDC HHS/United States
    U01 DP000248/DP/NCCDPHP CDC HHS/United States
    U01 DP000250/DP/NCCDPHP CDC HHS/United States
    U01 DP000254/DP/NCCDPHP CDC HHS/United States
No Related Documents.
You May Also Like: